135 related articles for article (PubMed ID: 32305307)
21. Review of
Gusman M; Aminsharifi JA; Peacock JG; Anderson SB; Clemenshaw MN; Banks KP
Radiographics; 2019; 39(3):822-841. PubMed ID: 31059396
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of [
Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
[TBL] [Abstract][Full Text] [Related]
23. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
[No Abstract] [Full Text] [Related]
24. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
25. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases.
Chen B; Macapinlac HA; Lu Y
Clin Nucl Med; 2019 Apr; 44(4):337-338. PubMed ID: 30688749
[TBL] [Abstract][Full Text] [Related]
26. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
[TBL] [Abstract][Full Text] [Related]
27. Needle track recurrence after transrectal prostate biopsy detected by ¹⁸F-Choline PET-CT.
Garcia-Bennett J; Henríquez I; Zugazaga Cortazar A; Fuertes J
Rev Esp Med Nucl Imagen Mol; 2015; 34(2):128-9. PubMed ID: 25037682
[No Abstract] [Full Text] [Related]
28. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
30. 18F-Fluciclovine-Avid Pulmonary Hamartoma.
Baldeosingh SC; Rowe SP; Greco SC; Paller CJ; Goel R
Clin Nucl Med; 2021 Nov; 46(11):919-921. PubMed ID: 34582137
[TBL] [Abstract][Full Text] [Related]
31. 18F-Fluciclovine Uptake in a Ureterocele.
Bitar R; Szklaruk J; Martiniova L; Zurita AJ; Chery LJ; Ravizzini G
Clin Nucl Med; 2021 Jan; 46(1):e3-e5. PubMed ID: 32956112
[TBL] [Abstract][Full Text] [Related]
32. Comparison of
Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
[TBL] [Abstract][Full Text] [Related]
33. Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard.
Tulipan AJ; Hole KH; Vlatkovic L; Revheim ME; Reijnen JS; Willoch F; Seierstad T; Lilleby W
Acta Radiol; 2019 Aug; 60(8):1028-1038. PubMed ID: 30379559
[No Abstract] [Full Text] [Related]
34. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
[TBL] [Abstract][Full Text] [Related]
35. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
36. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
37.
Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
[TBL] [Abstract][Full Text] [Related]
38. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
39. Imaging of Prostate Cancer Using Fluciclovine.
Savir-Baruch B; Zanoni L; Schuster DM
PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.
Suzuki H; Inoue Y; Fujimoto H; Yonese J; Tanabe K; Fukasawa S; Inoue T; Saito S; Ueno M; Otaka A
Jpn J Clin Oncol; 2016 Feb; 46(2):152-62. PubMed ID: 26732384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]